VBI Vaccines Inc. (VBIV)
NASDAQ: VBIV · IEX Real-Time Price · USD
0.580
-0.015 (-2.50%)
Jul 22, 2024, 9:58 AM EDT - Market open
VBI Vaccines Employees
As of December 31, 2023, VBI Vaccines had 138 total employees, including 131 full-time and 7 part-time employees. The number of employees decreased by 58 or -29.59% compared to the previous year.
Employees
138
Change (1Y)
-58
Growth (1Y)
-29.59%
Revenue / Employee
$68,196
Profits / Employee
-$608,623
Market Cap
16.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Lyra Therapeutics | 88 |
Kindly MD | 65 |
Biotricity | 55 |
Sensei Biotherapeutics | 28 |
Microbot Medical | 22 |
Aeterna Zentaris | 12 |
Aptorum Group | 3 |
PharmaCyte Biotech | 2 |
VBIV News
- 26 days ago - VBI Vaccines Announces Results of Annual General Meeting - Business Wire
- 7 weeks ago - VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients - Business Wire
- 2 months ago - VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients - Business Wire
- 2 months ago - VBI Vaccines Reports First Quarter 2024 Financial Results - Business Wire
- 3 months ago - VBI Vaccines Reports Full Year 2023 Financial Results - Business Wire
- 3 months ago - VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
- 3 months ago - VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
- 3 months ago - VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma - Business Wire